DURADYNE DHC
Clinical safety rating: caution
Comprehensive clinical and safety monograph for DURADYNE DHC (DURADYNE DHC).
DURADYNE DHC contains dihydrocodeine, an opioid agonist that binds to mu-opioid receptors in the CNS, inhibiting ascending pain pathways and altering pain perception and response.
| Metabolism | Metabolized primarily via CYP2D6 and CYP3A4 to active metabolite dihydromorphine; also undergoes glucuronidation. |
| Excretion | Primarily renal excretion of metabolites; ~90% excreted in urine as glucuronide conjugates and morphine; ~10% in feces via bile. |
| Half-life | Terminal elimination half-life of dihydrocodeine is approximately 4 hours; clinically relevant for dosing interval of 4-6 hours. |
| Protein binding | ~20% bound to plasma proteins (primarily albumin). |
| Volume of Distribution | 1.2 L/kg; indicates extensive tissue distribution, including CNS. |
| Bioavailability | Oral: ~20% due to first-pass metabolism; rectal: similar to oral. |
| Onset of Action | Oral: 30-45 minutes; Intramuscular: 15-30 minutes. |
| Duration of Action | 4-6 hours for analgesic effect; may be prolonged in hepatic/renal impairment. |
1 tablet (10 mg hydrocodone/300 mg acetaminophen) orally every 4-6 hours as needed for pain; maximum 8 tablets per day.
| Dosage form | TABLET |
| Renal impairment | eGFR 30-50 mL/min: reduce dose by 25% and increase interval to 6-8 hours; eGFR 15-29 mL/min: reduce dose by 50% and increase interval to 8-12 hours; eGFR <15 mL/min: avoid use if possible, otherwise use 25% of usual dose every 12 hours. |
| Liver impairment | Child-Pugh A: no adjustment; Child-Pugh B: reduce dose by 50% and increase interval to 8 hours; Child-Pugh C: avoid use. |
| Pediatric use | Weight-based dosing for hydrocodone: 0.1-0.2 mg/kg/dose (maximum 10 mg/dose) orally every 4-6 hours; for acetaminophen: 10-15 mg/kg/dose (maximum 650 mg/dose) every 4-6 hours; use lowest effective dose; not recommended under 2 years. |
| Geriatric use | Start at low end of dosing range (e.g., 1 tablet every 6-8 hours) due to increased sensitivity and risk of respiratory depression; monitor renal function; avoid in those with creatinine clearance <50 mL/min if possible. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for DURADYNE DHC (DURADYNE DHC).
| Breastfeeding | Dihydrocodeine and its active metabolite (dihydromorphine) are excreted into breast milk. Milk-to-plasma ratio (M/P) is approximately 0.6-1.2 based on limited data. Relative infant dose is estimated at 2-4% of maternal weight-adjusted dose. Caution is advised: monitor infant for sedation, poor feeding, and respiratory depression. Breastfeeding is generally discouraged with high maternal doses or prolonged use. The American Academy of Pediatrics considers dihydrocodeine as usually compatible with breastfeeding, but use the lowest effective dose for the shortest duration. |
| Teratogenic Risk | DURADYNE DHC contains dihydrocodeine, an opioid. First trimester: Risk of congenital malformations is low but not zero; case-control studies suggest a possible association with neural tube defects (odds ratio ~1.2-1.5) and some heart defects. Second trimester: No specific major structural anomalies reported; risk of spontaneous abortion may be slightly increased with chronic use. Third trimester: High risk of neonatal opioid withdrawal syndrome (NOWS) with chronic maternal use; also risk of respiratory depression at birth if used shortly before delivery. |
■ FDA Black Box Warning
Risk of medication errors; Addiction, abuse, and misuse; Life-threatening respiratory depression; Accidental ingestion; Neonatal opioid withdrawal syndrome; Interaction with alcohol or CNS depressants; Concomitant use with CYP3A4 inducers or discontinuation of CYP3A4 inhibitors may cause fatal respiratory depression.
| Serious Effects |
["Significant respiratory depression","Acute or severe bronchial asthma in an unmonitored setting or without resuscitative equipment","Known or suspected gastrointestinal obstruction, including paralytic ileus","Hypersensitivity to dihydrocodeine or any component of the product"]
| Precautions | ["Life-threatening respiratory depression","Addiction and abuse potential","Neonatal opioid withdrawal syndrome","Risks from concomitant use with benzodiazepines or CNS depressants","Adrenal insufficiency","Severe hypotension","Seizures","Serotonin syndrome with serotonergic drugs"] |
Loading safety data…
| Fetal Monitoring | Maternal: Assess pain scores, respiratory rate (target >12/min), and sedation level (Ramsay scale). Monitor for constipation and urinary retention. Fetal: Regularly assess fetal growth by ultrasound (serial growth scans every 4-6 weeks) and amniotic fluid volume. Nonstress test and biophysical profile weekly after 32 weeks if chronic use. Newborn: Observe for signs of neonatal opioid withdrawal syndrome (Finnegan score) for at least 48-72 hours after delivery. |
| Fertility Effects | Dihydrocodeine may cause hyperprolactinemia via dopamine receptor antagonism in the pituitary, potentially leading to galactorrhea and menstrual irregularities, which could impair fertility. In males, long-term opioid use can reduce libido, cause erectile dysfunction, and lower testosterone levels. Reversible upon discontinuation. |